SlowBull
The Business Brief WEDNESDAY, 2 SEPTEMBER 2026
← All stories
Markets

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

1 source ·1 article ·1h ago

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·1h ago

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.